97 related articles for article (PubMed ID: 15295773)
1. Interest in services among prostate cancer patients receiving androgen deprivation therapy.
Shapiro PJ; Coyne JC; Kruus LK; Palmer SC; Vaughn DJ; Malkowicz SB
Psychooncology; 2004 Aug; 13(8):512-25. PubMed ID: 15295773
[TBL] [Abstract][Full Text] [Related]
2. Information needs of men on androgen deprivation therapy.
Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
4. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy.
Chipperfield K; Fletcher J; Millar J; Brooker J; Smith R; Frydenberg M; Burney S
Psychooncology; 2013 Oct; 22(10):2169-76. PubMed ID: 23483679
[TBL] [Abstract][Full Text] [Related]
5. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.
Saini A; Berruti A; Cracco C; Sguazzotti E; Porpiglia F; Russo L; Bertaglia V; Picci RL; Negro M; Tosco A; Campagna S; Scarpa RM; Dogliotti L; Furlan PM; Ostacoli L
Urol Oncol; 2013 Apr; 31(3):352-8. PubMed ID: 21803612
[TBL] [Abstract][Full Text] [Related]
6. Perceptions of physically active men with prostate cancer on the role of physical activity in maintaining their quality of life: possible influence of androgen deprivation therapy.
Keogh JW; Patel A; MacLeod RD; Masters J
Psychooncology; 2013 Dec; 22(12):2869-75. PubMed ID: 23904113
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
[TBL] [Abstract][Full Text] [Related]
8. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.
Pirl WF; Siegel GI; Goode MJ; Smith MR
Psychooncology; 2002; 11(6):518-23. PubMed ID: 12476433
[TBL] [Abstract][Full Text] [Related]
9. Experiences of Unmet Need and Access to Supportive Care for Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Bi-national Study.
Paterson C; Primeau C; Howard N; Xiberras P; Pillay B; Crowe H
Semin Oncol Nurs; 2020 Aug; 36(4):151049. PubMed ID: 32703715
[TBL] [Abstract][Full Text] [Related]
10. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer.
Timilshina N; Breunis H; Alibhai S
Cancer; 2012 Apr; 118(7):1940-5. PubMed ID: 22009684
[TBL] [Abstract][Full Text] [Related]
11. Impact of Androgen Deprivation Therapy on Sexual and Hormonal Function in Patients Receiving Radiation Therapy for Prostate Cancer.
Kushnir T; Gofrit ON; Elkayam R; Paluch-Shimon S; Lawrence YR; Weiss L; Symon Z
Isr Med Assoc J; 2016 Jan; 18(1):49-53. PubMed ID: 26964281
[TBL] [Abstract][Full Text] [Related]
12. Health-Related Quality of Life and Its Associated Factors in Prostate Cancer Patients Who Receive Androgen Deprivation Therapy.
Chien CH; Chuang CK; Liu KL; Wu CT; Pang ST; Chang YH
Cancer Nurs; 2021; 44(1):E34-E42. PubMed ID: 31743152
[TBL] [Abstract][Full Text] [Related]
13. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.
Donovan KA; Walker LM; Wassersug RJ; Thompson LM; Robinson JW
Cancer; 2015 Dec; 121(24):4286-99. PubMed ID: 26372364
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
15. Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy.
Kim SH; Seong DH; Yoon SM; Choi YD; Choi E; Song H
Eur J Oncol Nurs; 2017 Oct; 30():84-90. PubMed ID: 29031319
[TBL] [Abstract][Full Text] [Related]
16. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
[TBL] [Abstract][Full Text] [Related]
17. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
18. Long-term impact of androgen-deprivation therapy on physical function and quality of life.
Alibhai SM; Breunis H; Timilshina N; Naglie G; Tannock I; Krahn M; Warde P; Fleshner NE; Canning SD; Tomlinson G
Cancer; 2015 Jul; 121(14):2350-7. PubMed ID: 25809861
[TBL] [Abstract][Full Text] [Related]
19. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
Alibhai SM; Breunis H; Timilshina N; Johnston C; Tomlinson G; Tannock I; Krahn M; Fleshner NE; Warde P; Canning SD; Klotz L; Naglie G
J Clin Oncol; 2010 Dec; 28(34):5038-45. PubMed ID: 21041715
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
